Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 764198 in Healthy Japanese Men
NCT04665700Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of apecotrep in focal segmental glomerulosclerosis (FSGS) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of subjects with drug-related adverse events up to 34 days. Started Feb 2021; status: completed.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT04665700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665700.